{"id":"khk7791","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3304485","moleculeType":"Small molecule","molecularWeight":"1145.07"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KHK7791 selectively inhibits Factor XIa, an enzyme in the intrinsic coagulation pathway. By blocking Factor XIa, the drug reduces the amplification of thrombin generation while potentially preserving hemostasis through the extrinsic pathway, offering a mechanism that may provide antithrombotic benefit with reduced bleeding risk compared to conventional anticoagulants.","oneSentence":"KHK7791 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key coagulation cascade enzyme, thereby reducing thrombotic risk.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:52.553Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thrombotic disorders and stroke prevention (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT03831607","phase":"PHASE2","title":"A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2018-12-27","conditions":"Hyperphosphatemia","enrollment":67},{"nctId":"NCT03864458","phase":"PHASE2","title":"Dose-finding Study of KHK7791 in Hyperphosphatemia Patients","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2019-04-15","conditions":"Hyperphosphatemia","enrollment":207},{"nctId":"NCT03864445","phase":"PHASE2","title":"Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2019-04-29","conditions":"Hyperphosphatemia","enrollment":47},{"nctId":"NCT04771780","phase":"PHASE3","title":"Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2021-03-15","conditions":"Hyperphosphatemia","enrollment":213},{"nctId":"NCT04766385","phase":"PHASE3","title":"Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2021-03-03","conditions":"Hyperphosphatemia","enrollment":54},{"nctId":"NCT04766398","phase":"PHASE3","title":"Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2021-03-15","conditions":"Hyperphosphatemia","enrollment":169},{"nctId":"NCT04767581","phase":"PHASE3","title":"Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2021-03-08","conditions":"Hyperphosphatemia","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tenapanor"],"phase":"phase_3","status":"active","brandName":"KHK7791","genericName":"KHK7791","companyName":"Kyowa Kirin Co., Ltd.","companyId":"kyowa-kirin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KHK7791 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key coagulation cascade enzyme, thereby reducing thrombotic risk. Used for Thrombotic disorders and stroke prevention (Phase 3 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":7,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}